Earnings Call Summary | Sera Prognostics(SERA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Sera Prognostics(SERA.US) Q1 2024 Earnings Conference
The following is a summary of the Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript:
以下是Sera Prognostics, Inc.（SERA）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Sera Prognostics reported a net revenue of $0 for Q1 2024 due to adjustments as part of their normal revenue recognition process, although gross revenues before adjustments were approximately $39,000.
Total operating expenses for Q1 were $9.1 million, down 20% year-over-year.
The net loss for the quarter decreased 24% to $8.1 million.
The company's cash and available-for-sale securities improved to $85.4 million as of March 2024.
Sera Prognostics报告称，由于作为正常收入确认流程的一部分进行了调整，2024年第一季度的净收入为0美元，尽管调整前的总收入约为39,000美元。
第一季度的总运营支出为910万美元，同比下降20％。
该季度的净亏损下降了24％，至810万美元。
截至2024年3月，该公司的现金和可供出售证券增至8,540万美元。
Business Progress:
业务进展：
Sera Prognostics is focusing on increasing test adoption and improving product margins.
The company has made progress on strategic priorities like submitting PRIME study findings, improving test analysis process cost-effectiveness, increasing awareness of PreTRM birth, and expanding into international markets.
Shipping of newly validated ambient whole blood collection kits to customers has begun, which is expected to reduce costs and increase patient access.
Plans are in place to share data from their AVERT and PRIME studies with potential international partners and regulators.
The FDA's final rule on Laboratory-Developed Tests (LDTs) is deemed potentially advantageous by the company.
Sera Prognostics专注于提高测试采用率和提高产品利润率。
该公司在战略优先事项上取得了进展，例如提交PRIME研究结果，提高测试分析过程的成本效益，提高对preTRM出生的认识以及向国际市场扩张。
新验证的环境全血采集套件已开始向客户发货，预计这将降低成本并增加患者获得的机会。
已计划与潜在的国际合作伙伴和监管机构共享其AVERT和PRIME研究的数据。
该公司认为FDA关于实验室开发测试（LDT）的最终规则具有潜在的优势。
More details: Sera Prognostics IR
更多详情： 红外血清预测
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。